VNDA Quote, Financials, Valuation and Earnings

Amicus Therapeutics has a net margin of -9.24% compared to Vanda Pharmaceuticals's net margin of -17.31%. Vanda Pharmaceuticals's return on equity of -3.49% beat Amicus Therapeutics's return on equity of -17.7%.

Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 189.19%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 159.74%. Given that Vanda Pharmaceuticals has higher upside potential than Amicus Therapeutics, analysts believe Vanda Pharmaceuticals is more attractive than Amicus Therapeutics.

Vanda Pharmaceuticals has a beta of 0.687, which suggesting that the stock is 31.259% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.979%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $53.2M, which are smaller than Amicus Therapeutics quarterly revenues of $125.2M. Vanda Pharmaceuticals's net income of -$4.9M is higher than Amicus Therapeutics's net income of -$21.7M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.28x versus 3.43x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -9.24% compared to Vanda Pharmaceuticals's net margin of -80.9%. Vanda Pharmaceuticals's return on equity of -3.49% beat Ultragenyx Pharmaceutical's return on equity of -194.36%.

Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 189.19%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $90.10 which suggests that it could grow by 169.6%. Given that Vanda Pharmaceuticals has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Vanda Pharmaceuticals is more attractive than Ultragenyx Pharmaceutical.

Vanda Pharmaceuticals has a beta of 0.687, which suggesting that the stock is 31.259% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.284%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $53.2M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $164.9M. Vanda Pharmaceuticals's net income of -$4.9M is higher than Ultragenyx Pharmaceutical's net income of -$133.4M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.28x versus 5.40x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of -9.24% compared to Vanda Pharmaceuticals's net margin of -62.96%. Vanda Pharmaceuticals's return on equity of -3.49% beat AVITA Medical's return on equity of -252.91%.

Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 189.19%. On the other hand AVITA Medical has an analysts' consensus of $17.17 which suggests that it could grow by 81.36%. Given that Vanda Pharmaceuticals has higher upside potential than AVITA Medical, analysts believe Vanda Pharmaceuticals is more attractive than AVITA Medical.

Vanda Pharmaceuticals has a beta of 0.687, which suggesting that the stock is 31.259% less volatile than S&P 500. In comparison AVITA Medical has a beta of 1.741, suggesting its more volatile than the S&P 500 by 74.135%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $53.2M, which are larger than AVITA Medical quarterly revenues of $18.4M. Vanda Pharmaceuticals's net income of -$4.9M is higher than AVITA Medical's net income of -$11.6M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.28x versus 3.81x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics has a net margin of -9.24% compared to Vanda Pharmaceuticals's net margin of -6020.94%. Vanda Pharmaceuticals's return on equity of -3.49% beat Vistagen Therapeutics's return on equity of -45.8%.

Vanda Pharmaceuticals has a consensus price target of $12.67, signalling upside risk potential of 189.19%. On the other hand Vistagen Therapeutics has an analysts' consensus of $13.00 which suggests that it could grow by 504.65%. Given that Vistagen Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe Vistagen Therapeutics is more attractive than Vanda Pharmaceuticals.

Vanda Pharmaceuticals has a beta of 0.687, which suggesting that the stock is 31.259% less volatile than S&P 500. In comparison Vistagen Therapeutics has a beta of 0.672, suggesting its less volatile than the S&P 500 by 32.794%.

Vanda Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vanda Pharmaceuticals pays -- of its earnings as a dividend. Vistagen Therapeutics pays out -- of its earnings as a dividend.

Vanda Pharmaceuticals quarterly revenues are $53.2M, which are larger than Vistagen Therapeutics quarterly revenues of $234K. Vanda Pharmaceuticals's net income of -$4.9M is higher than Vistagen Therapeutics's net income of -$14.1M. Notably, Vanda Pharmaceuticals's price-to-earnings ratio is -- while Vistagen Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vanda Pharmaceuticals is 1.28x versus 91.62x for Vistagen Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.